参考文献

1.Marchese MJ，Hall EJ，Hilaris BS，et al.Encapsulated iodine-125 in radiation oncology.Am J Clin Oncol，1984，7：607-611.

2.Freeman Ml，Goldhagen P，Sierra E，et al.Studies with encapsulated 125I sources：Determination of the relative biological effectiveness using cultured mammalian cells.Int J Radiat Oncol Biol Phys，1982，8：1355-1361.

3.Dale RG.The application of the linear-quadratic dose effect equation to fractionated and protracted radiotherapy.Br J Radiol，1985，58：515-528.

4.Siva VF，Gutin PH，Deen DF，et al.Relative biological effectives of 125I sources in a murine brachytherapy model.Int J Radiat Oncol Biol Phys，1984，10：2109-2111.

5.Dale RG.Radiobiological assessment of permanent implants using tumor repopulation in the liner-quadratic model.Br J Radiol，1989，62：241-244.

6.Denekamp J.Normal tissue response to radiation.In Bleehan N edi.Radiology in Radiotherapy，Berlin：Springer Verlag，1988，17-29.

7.Henschke UK，Lawrence DC.Caesium-137 seeds for permanent implants.Radiology，1985，1117-1119.

8.Hall EJ.Radiation dose rate：a factor of importance in radiobiology and radiotherapy.Br J Radiol，1972，45：81-97.

9.Ling CC.Permanent implants using 198Au、103Pa and 125I：Radiobiological considerations based on the liner quadratic model.Int J Radiat Oncol Biol Phys，1984，10：2109-2111.

10.De Silva VF Gutin PH，Deen DF，et，al.Relative biological effectiveness of 125I sources in a murine brachytherapy model.Int J Radiation Oncology Biol Phys，1984，10：2109-2111.

11.Marchese MJ，Zaider M，Hall EJ et al.Dose-rate effects in normal and malignant cells of human origin.Br J Radiol，1987，60：573-576.

12.Wheldon TE，Amin AE.The linear-quadratic model.Br J Radio，1988，62：700-702.

13.Begg AC，Moonen L，Hofland E et al.Human tumor cell kinetics using a monoclonal antibody against IUdR：intratumor sampling variation.Radiother Oncol，1988，11：337-347.

14.Eric B，Hall MA，Phil D，et al.Radiation dose-rate：a factor of importance in radiobiology andradiotherapy.Br J Radiol 1972，45：81-97.

15.Ling CC，Anderson LL，Shipley WU，et al.Dose inhomogeneity in intersitiial implants using 125I　seeds.Int J Radiat Oncol Biol Phys，1979，5：419-425.

16.Ling CC，Huang DY，Barnett C，et al.Improved dose distribution with customized 125I source loading in temporary interstitial implants.Int J Radiat Oncol Biol Phys，1988，15：769-774.

17.Ling CC，Huang DY，Narnett C，et al.The variation of OER with dose rate.Int J Radiat Oncol Biol Phys，1988，15：769-774.

18.Trott KR，Kummermehr W.What is known about tumour proliferation rates to choose between accelerated fractionation and hyperfractionation.Radiother Oncol，1985，3：1-9.

19.Mitchell JB，Bedford JS，Bailey SM.Dose-rate effects in mammalian cells in cultre.Ⅲ Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines.Radiat Res，1979，79：537-551.

20.Orton CG.Time-dose factors（TDFs）in brachtherapy.Br J Radiol，1974，47：603-607.

21.Orton CG，Webber BM.Time-dose factor（TDF）analysis of dose rate effects in permanent implant dosimetry.Int J Radiat Oncol Biol Phys，1977，2：55-60.

22.Philips T，GoffinetDL，Fu K，et al.Brachytherapy.Cancer Treat.Symp，1984，1：119-126.

23.Shipley WU，KopelsonG，Novack DJ，et al.Preoperative iiradiation，lymphadenectomy and 125I implant for selected patients with localize prostatic carcinoma：a correlation of implant dosimetry with clinical results，J Uro，1981，24：639-624.

24.Genest P，Hilaris BS，Nori D，et al.Iodine-125 as a substitute for iridium-192 in temporary intersititial implants.Endocur Hypertherm Oncol，1985，1：223-228.

25.Goffinet D，Ling CC，Mariscal M，et al.Using of 125I in breast implants.Endocur Hyperthem Oncol，1987，3：121-125.

26.Thames HD，Withers HR，Peters LJ，et al.Changes in early and late radiation response with altered dose fractionation：implications for dose-survival relationships.Int J Radiat Oncol Biol Phys，1982，8：219-226.

27.Wilson GD，McNally NJ，Dische S，et al.Measurement of cell kinetics in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry.Br J Can，1988，58：423-431.